Table 1.

Characteristics of included studies in the network meta-analysis.

Study	Study design	Sample size	Ratio of M/F	Biopsy class	Follow-up	Treatments drugs	Study quality
Gul et al. (6), Pakistan	RCT	28	All female	III, IV, V	24 weeks	MMF vs. CYC	3
Appel et al. (23), USA	RCT	370	1:1.5	III, IV, V	24 weeks	MMF vs. CYC	3
Wang et al. (7), China	PC	40	1:4.0	III, IV, V	12 months	TAC vs. CYC	7
Yap et al. (24), China	RCT	16	1:1.7	V	24 months	MMF vs. TAC	3
Goswami et al. (25), India	CT	83	1:17.1	III, IV, V	6 months	MMF vs. RTX	7
Basu et al. (14), India	RC	42	1:1.1	IV, V	36 months	RTX vs. MMF vs. CYC	4
Sundel et al. (26), UK	RCT	346	1:5.7	III, IV, V	24 weeks	MMF vs. CYC	6
Wang et al. (28), China	RCT	20	NA	IV	6 months	MMF vs. CYC	3
Lau et al. (29), USA	RT	13	1:12	III	6 months	MMF vs. CYC	5
El-Shafey et al. (30), Egypt	RCT	47	1:22.5	III, IV	24 weeks	MMF vs. CYC	3
Sedhain et al. (31), Nepal	RCT	42	1:7.4	III, IV, V	24 weeks	MMF vs. CYC	3
Feng et al. (32), China	RCT	53	1:7.6	III, IV, V	24 weeks	MMF vs. CYC	5
Mendonca et al. (33), India	RCT	37	1:4	III, IV, V	24 weeks	MMF vs. CYC	3
Onishi et al. (27), Japan	RT	21	All female	III, IV, V	24 weeks+	MMF vs. CYC	5
Joo et al. (34), Korea	CT	99	1:10	III, IV, V	12 months	MMF vs. CYC	7
Ong et al. (35), Malaysia	RCT	44	1:5.3	III, IV, V	6 months	MMF vs. CYC	5
Moroni et al. (15), Italy	CT	34	1:7.5	III, IV, V	12 months	RTX vs. MMF vs. CYC	5
Chen et al. (8), China	RCT	81	1:5.8	III, IV, V	6 months	TAC vs. CYC	5
Mok et al. (36), Hong Kong	RCT	150	1:11.5	V	6 months	MMF vs. TAC	5

CT, controlled trial; CYC, cyclophosphamide; M/F, male/female; MMF, mycophenolate mofetil; NA, not available; PC, prospective cohort; RC, retrospective cohort; RCT, randomized controlled trial; RTX, rituximab; TAC, tacrolimus.